Completed PHASE3 INTERVENTIONAL 4-arm NCT01229371

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers

Randomized, Parallel-group, Double-blind Multi-center Phase III Study to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers, in Elderly and Young Adults

Sponsor: Crucell Holland BV

Conditions Influenza

Interventions Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011 Inflexal V influenza vaccine (CSL HA Antigen) 2010

Updated 5 times since 2017 Last updated: Aug 29, 2013 Started: Oct 31, 2010 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Influenza, this trial is completed. The trial is conducted by Crucell Holland BV and has accumulated 5 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Crucell Holland BV

Data source: Crucell Holland BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Allschwil, Switzerland
• Arzo, Switzerland